In a number of complement-driven inflammatory diseases, such as aHUS, PNH, and neuromyelitis optica, 2 antibody-based C5 inhibitors targeting the same epitope on C5_MG7 currently represent the only approved treatments (14, 27). This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.